



3 January 2017  
EMA/764474/2016

## Agenda: Multi-stakeholder paediatric oncology strategy (ALK-driven diseases)

30-31 January 2017, room 03-E

Item	Preliminary agenda 30 January 2017
1.	Welcome and introduction
2.	Biology of anaplastic lymphoma kinase (ALK) in paediatric malignancies – translocation, mutation, amplification, copy number gain and expression
3.	Therapeutic Needs in the paediatric population
3.1	Inflammatory Myofibroblastic Tumour (IMT)
3.2	Anaplastic large cell lymphoma (ALCL)
3.3	Neuroblastoma
3.4	Rhabdomyosarcoma
4.	Academic data of ALK inhibitors in relevant paediatric pre-clinical models
5.	Pharmaceutical industry data on ALK inhibition
	End of Day One

Item	Preliminary agenda 31 January 2017
5	Pharmaceutical industry data on ALK inhibition (cont.)
6.	Overall Perspective and conclusion
7.	End of meeting

